Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients
| Autor: | Thue Orsnes, Michael Soelberg, Peter Gebuhr, Henrik Wilbek |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Naproxen medicine.medical_specialty Time Factors medicine.medical_treatment Administration Oral Placebo Preoperative care Prosthesis law.invention Randomized controlled trial Double-Blind Method law Preoperative Care medicine Humans Orthopedics and Sports Medicine Prospective Studies Prospective cohort study Aged Postoperative Care Ossification business.industry Ossification Heterotopic Suppositories Middle Aged medicine.disease Surgery Anesthesia Heterotopic ossification Hip Prosthesis medicine.symptom business medicine.drug |
| Zdroj: | Acta orthopaedica Scandinavica. 62(3) |
| ISSN: | 0001-6470 |
| Popis: | The effect of naproxen on heterotopic ossification after total hip replacement was studied in a randomized, double-blind trial. Twenty-eight patients received 250 mg naproxen thrice daily for 4 weeks postoperatively starting on the morning of the operation while 27 control patients received a placebo. Three months after the operation, 13 patients in the control group had heterotopic ossification compared with 4 patients in the group that received naproxen; and after 1 year, the figures were 15 and 4, respectively (P less than 0.01). Three control patients had severe ossifications. We conclude that naproxen given for 4 weeks is sufficient to decrease the incidence of heterotopic ossification after cemented total hip replacement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|